Evidence map›Paper›PMID 33754257›Full record

ArticlePharmaceutical research2021

Application of Affinity-Capture Self-Interaction Nanoparticle Spectroscopy in Predicting Protein Stability, Especially for Co-Formulated Antibodies.

Meng Zhou, Zhen Yan, Hao Li, Xun Liu, Piaoyang Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Meng ZhouSchool of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Zhen YanShanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, 200245, China.
Hao LiShanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, 200245, China.
Xun LiuShanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, 200245, China. liuxun@shhrp.com.
Piaoyang SunSchool of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. sunpiaoyang@126.com.ORCID http://orcid.org/0000-0003-3929-8580
Jiangsu Hengrui Medicine (China) · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFrom traditional monoclonal antibodies to more and more complex mAb-based formulations, biopharmaceutical faces one challenge after another. To avoid these issues, identification of therapeutic proteins in the initial discovery process that has high stability and low self-interaction would simplify the development of safe and effective antibody therapeutics.

methodAffinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) is a new prediction method capable of identifying mAbs with different self-association propensity. In this study, 10 formulated monoclonal antibody (mAb) therapeutics include different mAb isotypes and co-formulated antibodies were measured by AC-SINS and some biophysical methods to predict protein stability. The prediction results of all 10 mAbs were compared to their stability data (Δ%monomer and Δ%HMWs) at accelerated (25°C and 40°C) and long-term storage conditions (4°C) as measured by size exclusion chromatography.

resultAC-SINS method has a good predictive correlation with each mAbs and co-formulated antibodies. There were no physicochemical, intermolecular, or biological interactions that occurred between the two components of co-formulated antibodies which confirmed by Analytical ultracentrifugation (AUC).

conclusionHere we discuss the correlation between each method and protein stability, and also use AC-SINS assay to predict the stability of co-formulated antibodies for the first time. This may be an effective way to predict the stability of these complex mAb-based formulations such as co-formulated mAbs.

Indexed as

Antibodies, MonoclonalChemistry, PharmaceuticalChromatography, GelDrug StabilityNanoparticlesProtein AggregatesProtein StabilitySolubilitySpectrum AnalysisUltracentrifugationViscosityAntibodies, MonoclonalProtein AggregatesAC-SINSAUCco-formulated antibodiesprotein-protein interactionself-association

Identifiers

PMID33754257
OpenAlexW3137207445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.